KRAS and familial pancreatic carcinoma: The silencing of the two genes led to a strong inhibition in tumor cells’ proliferation without side effects on normal cells as selective targeting was guaranteed by the presence of FA and G12C mutant K-Ras siRNA, which is a mutation that is typical of pancreatic cancer cells.